CGTX News

Eight IPOs joined the public market this past week, joined by ten SPACs. Two companies postponed, both citing market conditions: fitness equipment brand iFIT Health & Fitness (IFIT) and drug developer AEON Biopharma (AEON). New filers continued to flood the pipeline, with 22 IPOs and 12 SPACs submitting initial filings. Canada-listed...read more

Cognition Therapeutics, a Phase 2 biotech developing small molecule therapies for Alzheimer's and other CNS diseases, raised $45 million by offering 3.8 million shares at $12, within the range of $11 to $13. The company offered 0.4 million more shares than anticipated. Cognition Therapeutics is developing small molecule therapies for age-related degenerative diseases and disorders...read more

Cognition Therapeutics, a Phase 2 biotech developing small molecule therapies for Alzheimer's and other CNS diseases, announced terms for its IPO on Monday. The Purchase, NY-based company plans to raise $40 million by offering 3.4 million shares at a price range of $11 to $13. At the midpoint of the proposed range, Cognition Therapeutics would command a  fully diluted market...read more

Cognition Therapeutics, a Phase 2 biotech developing small molecule therapies for Alzheimer's and other CNS diseases, filed on Monday with the SEC to raise up to $50 million in an initial public offering. Cognition Therapeutics is developing small molecule therapies for age-related degenerative diseases and disorders of the CNS and the retina, with an initial aim to leverage...read more